Travere Therapeutics, Inc.TVTXNASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +65.98% | +97.54% | +111.49% | +162.11% | +73.41% |
| Gross Profit Growth | +152.19% | +93.26% | +170.75% | +166.47% | +50.90% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +8.67% | +14.55% | +14.77% | +14.72% | +8.65% |
| Weighted Average Shares Diluted Growth | +8.67% | +14.55% | +14.77% | +31.94% | +8.65% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +28.03% | +51.25% | +58.25% | +229.69% | +200.32% |
| Inventory Growth | -34.11% | -13.24% | -31.56% | -12.71% | -5.24% |
| Asset Growth | -24.69% | -17.29% | +0.76% | +6.77% | +1.86% |
| Book Value per Share Growth | -72.93% | -61.31% | +88.37% | +0.00% | +78.90% |
| Debt Growth | -0.79% | -0.88% | -0.91% | -18.06% | -15.37% |
| R&D Expense Growth | +5.65% | -59.09% | -9.14% | +0.41% | -6.76% |
| SG&A Expenses Growth | +31.80% | +13.41% | +40.02% | +31.75% | +46.32% |